Ixico Regulatory News (IXI)

20 March 2014

Results of AGM

IXICO plc (Ticker: IXI) ("IXICO" or the "Company"), the brain health company, announces that all resolutions put to its Annual General Meeting held earlier today were duly passed.

About IXICO

IXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and more recently launched into the wider clinical diagnostic market. Since incorporation, IXICO has been awarded contracts by nine of the top 15 global pharmaceutical companies as well as leading biotechnology companies. In October 2013, IXICO plc was admitted to trading on AIM. More information is available on www.ixico.com

Enquiries:

IXICO plc 

Derek Hill, CEO

Charles Spicer, VP Corporate Development

+44 20 7691 2064

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel

Clare Terlouw

+44 20 7418 8900

Daniel Stewart & Company (Joint Broker)

Mark Treharne

David Hart

+44 207 776 6550

FTI Consulting Limited (Investor Relations)

Ben Atwell

Simon Conway

John Dineen

+44 20 3727 1000